Clorox Reports Q1 Fiscal Year 2027 Results, Updates Outlook

Clorox reported fiscal Q1 2027 net sales of $1.91 billion, up 33% year over year, and adjusted EPS of $1.55, up 82%; GOJO contributed about 15 percentage points to sales growth, while lapping the prior-year ERP-related inventory drawdown also lifted comparisons. Gross margin fell 130 basis points to 40.4% amid higher commodity, manufacturing and logistics costs. Clorox maintained its FY2027 sales outlook of 13%–14% growth and adjusted EPS range of $5.70–$6.00, but updated its gross-margin outlook to about 41.5% and said it expects adjusted EPS near the low end of the range due to higher inflationary pressures.

Analysis

The quality of the beat is weaker than the headline growth suggests: the ERP comparison explains most of the organic growth, while higher commodity, manufacturing and logistics costs are already pushing the full-year gross-margin outlook down. Household and Lifestyle volume gains are especially poor evidence of durable demand because management attributes them primarily to the same comparison effect. The key 1–3 month test is whether shipments hold after that benefit fades—and whether cost savings and pricing can deliver the guided 41.5% full-year gross margin. With adjusted EPS now expected nearer the low end, unchanged guidance is not a clean de-risking signal.

GOJO adds a potentially valuable professional/healthcare channel, but the near-term economics are less certain than its revenue contribution: integration costs, inventory step-up and B2B channel requirements complicate margin conversion. Ecolab and Kimberly-Clark Professional are relevant competitive reference points, but the launch alone does not establish share gains. The balance sheet also merits attention: debt is substantial relative to cash, and quarterly interest expense is higher year over year, limiting flexibility if integration or inflation disappoints.

Contrarian read: investors may over-credit both acquisition-led growth and the ERP lap as evidence of a demand recovery. Conversely, a durable Purell ProCare cross-sell opportunity could be underappreciated—but needs evidence in organic growth and segment margins, not launch claims. Structural upside is a 6–18 month question; near-term risk is margin execution.

Key Decisions for Investors

• Avoid chasing CLX on the reported growth. Consider a modest relative-value short in CLX versus XLP after any post-call relief rally, rather than an outright short; the thesis is weak underlying growth plus margin pressure, not a collapse in household demand.
• Reassess over the next 1–3 months using organic sales excluding the ERP comparison, gross-margin progression toward the 41.5% full-year guide, and management’s confidence in the low-to-high end of adjusted EPS. Failure to stabilize margins or evidence of post-lap shipment deceleration strengthens the underweight.
• Falsifiers: sustained underlying volume growth after the ERP benefit rolls off, margin recovery consistent with the annual guide despite inflation, or demonstrable GOJO-related cross-selling and segment profitability. Verify retailer inventory and acquired-business contribution before treating sales growth as end-demand.
• Watch debt and cash-flow disclosures alongside integration progress. A further rise in financing costs or weaker operating cash conversion would increase downside sensitivity; do not infer acquisition synergies from the quarter’s consolidated sales growth.